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OBJECTIVE—We have hypothesized that variation in imprinted
growth-promoting fetal genes may affect maternal glucose con-
centrations in pregnancy. To test this hypothesis we evaluated
the effects of fetal disruption of murine H19
13 on maternal
glucose concentrations in pregnancy.
RESEARCH DESIGN AND METHODS—Experimental mice
were pregnant females that had inherited the disrupted H19
13
from their fathers and were therefore phenotypically wild type
due to imprinting; approximately half of their litters were null for
H19
13 through maternal inheritance of the disrupted gene. In
control mice approximately half the litter paternally inherited the
disrupted H19
13, so the pups were either genetically wild type
or phenotypically wild type due to imprinting. Blood glucose
concentrations were assessed by intraperitoneal glucose toler-
ance tests on days 1, 16, and 18 of pregnancy.
RESULTS—There were no differences in the glucose concentra-
tions of control and experimental pregnant mice at day 1.
However, at day 16 mothers carrying H19
13-null pups had a
signiﬁcantly higher area under the glucose tolerance test curves
than controls (1,845  378 vs. 1,386  107 mmol  min  l
1 [P 
0.01]) in association with increasing pregnancy-related insulin
resistance. Although this difference lessened toward term, over-
all, mothers of maternally inherited H19
13 mutants had signif-
icantly higher glucose concentrations during the last trimester
(1,602  321 [n  17] vs. 1,359  147 [n  18] mmol  min  l
1
[P  0.009]).
CONCLUSIONS—This study provides evidence that maternal
glucose concentrations in pregnant mice can be affected by
targeted disruption of fetal H19
13. This implies that variable
fetal IGF2 expression could affect risk for gestational diabetes.
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G
estational diabetes mellitus (GDM) has tradi-
tionally been considered a condition originat-
ing through combined effects of maternal
genetics (1,2) and her environment, including
effects associated with maternal obesity. The current
increasing incidence of GDM (3) is thought to result from
the increasing prevalence of obesity, with effects of the
associated insulin resistance combining with those of the
physiological insulin resistance of pregnancy to impair
glucose tolerance.
Following Haig’s suggestion (4) that maternal metabo-
lism during pregnancy could be inﬂuenced by variation in
the fetal genome, we recently proposed that risk of GDM
could also be modiﬁed by variation in the fetal genome,
particularly in fetal growth genes (5). This might occur as
part of the genetic conﬂict of pregnancy where maternal
genes limit fetal growth and paternally inherited fetal
genes enhance it by increasing the amount of metabolic
fuel supplied by the mother to the fetus (6). Candidates
include imprinted genes, where expression of transmitted
alleles depends on their parent of origin (7,8). Preliminary
evidence for this phenomenon comes from our studies of
contemporary birth cohorts that have shown that both
third-trimester maternal glucose tolerance and offspring
birth weights are associated with common polymorphic
variation in the H19 gene (9), which is reciprocally im-
printed with respect to IGF2 and regulates its imprinting
and expression.
The following study was therefore performed to test the
hypothesis that changes in maternal glucose concentra-
tions during pregnancy could be mediated by genetic
variation in the murine fetal H19 region (5), which is
usually expressed only from the maternally inherited fetal
allele, using mice with targeted disruption of H19
13 that
are born 30% heavier than controls (10,11).
RESEARCH DESIGN AND METHODS
Animals. All experiments were performed under the Animals (Scientiﬁc
Procedures) Act 1986 after Cambridge University Animal Ethics Committee
approval. The mice were kept under controlled conditions with a 12-h
light/dark cycle and had free access to food and water throughout (except
during the glucose tolerance test [GTT] starvation period when only water
was available).
H19
13/ mice (in which insertion of a neomycin resistance cassette
originally replaced the entire 3-kb coding region of the gene and the 10-kb 5
ﬂanking region including the Igf2 control region [10,12]) were bred on
C57BL/6 backgrounds and their offspring genotyped by PCRs of ear biopsy
DNA (extracted using DNeasy kits; Qiagen, Crawley, U.K.). The 20-l reaction
mix contained 2 units of BIO-X-ACT polymerase (Bioline Ltd., London, U.K.),
10 l Buffer A (Bioline), 8 pmol of forward (5-TGCCACAGAGGAAGAAAC-
CAG-3) and reverse (5-AGTCATAGCCGAATAGCC-3) oligonucleotide prim-
ers, and 25 ng DNA. The reaction mix was incubated at 94°C for 7 min and
then 20 cycles of 94°C (30 s), 49°C (30 s) dropping 0.5°C each cycle, and 72°C
(1 min). After this, the mix underwent 30 cycles of 94°C (30 s), 39°C (30 s), and
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282 DIABETES, VOL. 59, JANUARY 2010 diabetes.diabetesjournals.org72°C (1 min) and a ﬁnal incubation at 72°C (10 min). Knockout mice produced
a 895-bp band when separated electrophoretically on a 1% (wt/vol) agarose
gel. Presence of the wild-type H19 gene was tested using similar reaction
conditions but a different reverse primer (5-TTCAGTCACTTCCCTCAGCCTC-
3) and increasing the annealing temperatures by 10°C throughout to produce
a 494-bp band.
The aim of our breeding program was to produce experimental dams, in
which approximately half of their litter was H19
13 null due to inheriting the
disrupted gene from their mothers, and control dams, in which approximately
half of their genetically matched litter inherited the disrupted H19
13 from
their fathers and were therefore phenotypically wild type due to imprinting.
To achieve this, experimental females were genotypically heterozygous
knockout mice (H19
13/) that were phenotypically wild type due to
paternal inheritance of the disrupted gene and were mated to wild-type
C57BL/6 male mice (Charles River Ltd., Margate, U.K.) (Fig. 1). Controls were
wild-type C57BL/6 females mated to genotypically heterozygous H19
13/
males. Due to imprinting, the genotype, but not the gene expression distribu-
tion among the pups, was therefore the same for both groups. Pregnancy was
assumed at the expulsion of a vaginal plug (day 0), although for the studies on
days 16 and 18 of pregnancy only those animals who gained weight suggestive
of pregnancy were assessed.
Glucose tolerance tests. For each day, 8–10 different experimental and
control mice had their glucose concentrations assessed on day 1, 16, or 18 of
pregnancy (day 1 was used as baseline; the other days were used because in
previous experiments using an alternative mouse model in which placental
Igf2 expression was manipulated, there were differences in effects on placen-
tal nutrient transport among these days [13]). The animals were starved for
15 h and were then tail bled to produce samples for the measurement of blood
glucose and other analytes. The mice were then injected intraperitoneally with
1 g/kg body wt glucose (administered as a 10% [wt/vol] solution). Further
blood glucose measurements were then taken 15, 30, 60, 120, and 180 min
later.
Blood glucose, serum insulin, and Igf-ii concentrations. Blood glucose
was measured using a 201 glucose meter (Hemocue Ltd., Shefﬁeld, U.K.).
Fasting serum Igf-ii (following standard acid-ethanol extraction and neutral-
ization; RayBiotech Mouse Igf-ii ELISA; Innovate Biotechnology, London,
U.K.) and insulin (Linco Rat & Mouse Insulin ELISA; Millipore, London, U.K.)
concentrations were measured by enzyme-linked immunosorbent assay
(ELISA) according to the manufacturer’s instructions. Fasting insulin sensi-
tivity was assessed indirectly by homeostasis model assessment (HOMA)
(http://www.dtu.ox.ac.uk/index.php?maindoc/homa/index.php). Although its
underlying principles are invalid in rodents (14), the values produced by this
model do correlate with hyperinsulinemic-euglycemic clamp measures of
insulin sensitivity in mice (15) without the need for prior surgery or general
anesthesia.
Statistical analysis. Glucose concentrations were assessed as areas under
the (0–180 min) glucose curves (AUCs), calculated using the trapezoid rule.
When comparing normally distributed data from two groups on a particular
day of pregnancy, Student t tests were used (having performed the Levine test
for equality of variances); otherwise, comparison was by Mann-Whitney U
test. Where overall comparisons were made using all 3 days of pregnancy in
the same model, two-way ANOVA was used with the experimental group and
day of pregnancy as the ﬁxed variable and glucose AUC as the dependent
variable. All statistical analysis was performed using SPSS, version 14.0 (SPSS,
Chicago). Data are presented as mean  SD for the GTT data and median
(interquartile range) for everything else. P  0.05 was considered statistically
signiﬁcant.
RESULTS
On day 1 of pregnancy there was no detectable difference
in glucose AUCs during the GTT between experimental
and control groups: 1,478  197 (n  10) vs. 1,708  318
(n  10) mmol  min  l( P  0.07). There were also no
detectable differences in fasting serum insulin or Igf-ii
concentrations or in insulin sensitivity (Table 1).
On day 16 of pregnancy, when H19
13/ pups weighed
on average 118% that of wild-type pups (supplementary
Table 1 in the online appendix, which is available at
http://diabetes.diabetesjournals.org/cgi/content/full/db09-
0757/DC1), all mice were more insulin resistant than on
day 1 (insulin sensitivity dropping as the day of preg-
nancy increased [P  0.002]). Experimental dams had
signiﬁcantly higher glucose AUCs than controls (P 
0.01, Fig. 2) despite having no detectable differences in
fasting insulin or Igf-ii concentrations or insulin sensi-
tivity (Table 1).
At day 18, when H19
13/ pups weighed on average
123% that of wild-type pups (supplementary Table 1), mice
carrying litters containing H19
13/ mice still had higher
mean glucose AUCs, but the difference was not statisti-
cally signiﬁcant (P  0.2, Fig. 3). There was no difference
in either day 18 fasting insulin or Igf-ii concentrations or in
insulin sensitivity (Table 1). Combining data from across
the third trimester, the experimental mice still had signif-
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FIG. 1. Schematic of the matings in the H19
13 knockout study. Male mice are represented by squares and female mice by circles. Wild-type mice
are represented by solid black shapes and heterozygote knockout mice by half-solid black shapes and half-striped shapes (the stripes are on the
left-hand side if the disrupted allele was inherited from the father and on the right-hand side if it was inherited from the mother). Penetrance
of the disrupted allele is estimated to be 50% in each case, and half of the offspring are assumed to be males. All the experimental mothers,
although they were heterozygous H19
13 knockouts, were phenotypically wild type due to having inherited the disrupted allele from their fathers
and imprinting.
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(n  17) vs. 1,359  147 (n  18) mmol  min  l
1 (P 
0.009).
There were no differences in the number of pups carried
by experimental and control mice (data not shown). Nor
was the number of pups carried correlated with any
measure of glucose concentrations in either of the groups.
No difference was made to the results of analyzing the area
under the GTT curves when adjusting for the numbers of
pups being carried (data not shown). When comparing
glucose AUCs on all the different days in the same
statistical model, there were signiﬁcant effects of both the
day of pregnancy (P  0.02) and the interaction between
the day of pregnancy and the group (P  0.001). Also, a
lowering of glucose AUCs between days 16 and 18 of
pregnancy was observed that was independent of group
(P  0.014; supplementary Table 2).
DISCUSSION
This study provides direct evidence that changes in murine
maternal glucose concentrations during pregnancy can be
mediated by alteration in a fetal growth gene, in this case
H19
13. Previously, there has been only indirect evidence
from humans to support this proposal (5), partially due to
the difﬁculty in differentiating effects of fetal genes on
maternal metabolism from effects of maternal genes. Evi-
dence implicating variation in fetal IGF2 expression
comes from the observed trend for an increased risk of
developing GDM in mothers carrying offspring with Beck-
with-Wiedemann syndrome (16). Additional indirect evi-
dence for the fetal genome modifying the risk for maternal
GDM comes from studies showing an increased risk in
women carrying males rather than smaller females (17),
and in multiple pregnancies (18).
Our studies provide further support for this hypothesis.
On day 1 of pregnancy there was no change in glucose
concentrations in mice carrying H19
13/ pups. However
by day 16 signiﬁcant increases in maternal glucose con-
centrations were observed in dams carrying H19
13/
pups despite overall similar decreases in HOMA-derived
insulin sensitivity in both groups. These raised glucose
concentrations could have resulted from reduced ﬁrst-
phase insulin secretion and/or insulin-stimulated glucose
uptakes, neither of which would have inﬂuenced HOMA
measurements.
Our mice also displayed a generalized lowering of
glucose concentrations between days 16 and 18, as has
recently been observed in another mouse model (19). This
may have limited our power to detect continuing differ-
ences between groups, as there was no effect of fetal
H19
13/ on maternal glucose concentrations evident on
day 18 of pregnancy. Whereas in humans it is known that
TABLE 1
Fasting plasma insulin and Igf-ii concentrations, with fasting insulin sensitivities on days 1, 16, and 18 of pregnancy in mice carrying
litters containing H19
13/ knockout pups
Experimental
mice Controls P
Day 1 (n  10) (n  10)
Insulin (pmol/l) 46 (35–74) 35 (35–61) 0.4
Igf-ii (ng/ml) All 6 All 6 1.0
Insulin sensitivity (HOMA %S) 113.9 (64.3–147.8) 140.0 (78.6–145.1) 0.8
Day 16 (n  8) (n  9)
Insulin (pmol/l) 137 (92–237) 112 (52–154) 0.3
Igf-ii (ng/ml) All 6 All 6 1.0
Insulin sensitivity (HOMA %S) 40 (23–61) 50 (40–119) 0.2
Day 18 (n  9) (n  9)
Insulin (pmol/l) 111 (63–279) 141 (83–1,472) 0.7
Igf-ii (ng/ml) All 6 All 6 1.0
Insulin sensitivity (HOMA %S) 52 (21–102) 40 (6–65) 0.8
Data are median (interquartile range).
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FIG. 2. Intraperitoneal GTT curves of pregnant mice carrying litters containing H19
13/ knockout pups on day 16 of pregnancy and total AUC
bar charts. Each time point in the GTT is presented as a mean  SEM, with the total AUCs as mean (95% CI).
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progresses (20), data relating to the very last weeks of
pregnancy corresponding to day 18 in the mouse are less
certain. Women with preexisting type 1 diabetes have a fall
in insulin requirements in the last 2 weeks of pregnancy
(21), suggesting a possible improvement in insulin sensi-
tivity. If effects on maternal glucose metabolism in our
mice were mediated by placental hormones (5), the gen-
eralized fall in maternal glucose concentrations at the end
of pregnancy may therefore have resulted from a prepar-
tum decrease in placental metabolic activity similar to that
which has been observed in other model systems (22).
H19
13 disruption affects Igf2 imprinting and expres-
sion, and fetal growth in mice (10,11). We hypothesize that
our results therefore relate to increased placental and fetal
Igf2 expression. However we cannot rule out a role for the
disruption of H19 per se or changes in 91H (antisense
H19) RNA expression (23). We propose that the increased
placental Igf2 expression, rather than causing changes in
maternal Igf-ii concentrations that were not detectably
raised in our mice, affects the expression and release of
metabolically active placental hormones into the maternal
circulation that worsens their glucose tolerance (5). Indi-
rect support for this comes from the enhanced lowering of
glucose concentrations we observed in H19
13/ mice
between days 16 and 18 of pregnancy, as at equivalent
stages in human pregnancies at least, placental protein
concentrations in the maternal circulation fall (24). One
candidate hormone for this process is mouse placental
lactogen II because its placental expression has been
linked to that of Igf2 (25), it regulates pancreatic 	-cell
expansion in pregnancy (26), and pregnant mice without
functional prolactin receptors, for which it is a ligand,
become glucose intolerant (19). These animal experimen-
tal data may be important in the understanding of the
pathogenesis of human GDM. Previously, we found that in
humans a common H19 polymorphism is associated with
variation in birth weight, maternal glucose concentrations,
and cord blood IGF-II concentrations (9). In humans, there
is a linear relationship between maternal glucose toler-
ance during pregnancy and birth weights, even in the
absence of GDM (27). Our study would suggest that this
may not be explained solely by maternal genetic and
environmental factors determining glucose concentrations
crossing the placenta and stimulating fetal insulin secre-
tion with ensuing fetal weight gain. These relationships
could be affected by the fetal genome inﬂuencing maternal
glucose concentrations by factors secreted by the placenta
into the maternal circulation. In conclusion, this study
provides the ﬁrst direct evidence that a variation in a fetal
gene affecting growth rates (10,11) may also alter maternal
glucose concentrations during pregnancy, in association
with increasing pregnancy-related insulin resistance, rais-
ing the possibility that this process could contribute to the
etiology of human GDM.
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